Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial (ADAPT)
The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar) injections less often while maintaining control of their disease.
The main question it aims to answer is: can adalimumab/biosimilar injections be given less frequently without uveitis (eye inflammation) or arthritis (joint inflammation) returning?
Researchers will compare adalimumab/biosimilar injection schedules of every 2 weeks, 4 weeks, 8 weeks, and 12 weeks to determine how injection frequency affects disease control.
Participants will:
- Take adalimumab/biosimilar injections every 2, 4, 8, or 12 weeks.
- Attend study visits every 6 weeks over 24 weeks, with an additional follow-up visit at 48 weeks for checkups, tests, and questionnaires.
- Keep a diary of how often they take adalimumab/biosimilar and other drugs they take for their uveitis/arthritis.
研究概览
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Nisha Acharya, MD MS
- 电话号码:415-476-8131
- 邮箱:Nisha.Acharya@ucsf.edu
学习地点
-
-
-
Florence、意大利、50139
- Meyer Children's Hospital
-
首席研究员:
- Gabriele Simonini
-
接触:
- Gabriele Simonini
- 电话号码:(+39) 05 55662924
- 邮箱:gabriele.simonini@unifi.it
-
首席研究员:
- Ilaria Maccora
-
-
-
-
California
-
Los Angeles、California、美国、90095
- University of California, Los Angeles
-
首席研究员:
- Edmund Tsui, MD
-
接触:
- Edmund Tsui, MD
- 电话号码:310-825-5440
- 邮箱:etsui@mednet.ucla.edu
-
Sacramento、California、美国、95817
- University of California, Davis
-
接触:
- Parisa Emami-Naeini, MD, MPH
- 电话号码:916-734-6602
- 邮箱:parisaemami@gmail.com
-
首席研究员:
- Parisa Emami-Naeini, MD MPH
-
首席研究员:
- Angel Herrera-Guerra, MD PhD
-
San Francisco、California、美国、94143
- University of California, San Francisco
-
首席研究员:
- Nisha Acharya, MD
-
接触:
- Nisha Acharya, MD MS
- 电话号码:415-476-8131
- 邮箱:Nisha.Acharya@ucsf.edu
-
副研究员:
- John Gonzales, MD
-
副研究员:
- Thuy Doan, MD PhD
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami
-
接触:
- Stephanie Llop, MD
- 邮箱:sxl1789@med.miami.edu
-
首席研究员:
- Stephanie Llop, MD
-
副研究员:
- Janet Davis, MD
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- Children's Mercy Hospital
-
接触:
- Erin Stahl, MD
- 电话号码:816-960-8000
- 邮箱:edstahl@cmh.edu
-
首席研究员:
- Ashley Cooper, MD
-
首席研究员:
- Erin Stahl, MD
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital
-
首席研究员:
- Virginia Miraldi Utz, MD
-
首席研究员:
- Sheila Angeles-Han, MD
-
接触:
- Sheila Angeles-Han, MD
- 电话号码:513-517-2057
- 邮箱:Sheila.Angeles-Han@cchmc.org
-
-
Tennessee
-
Nashville、Tennessee、美国、37212
- Vanderbilt University Medical Center
-
接触:
- Sapna Gangaputra, MD MPH
- 电话号码:615-936-3921
- 邮箱:sapna.gangaputra@vumc.org
-
首席研究员:
- Sapna Gangaputra, MD MPH
-
首席研究员:
- Thomas (Brent) Graham, MD MS
-
-
Texas
-
Austin、Texas、美国、78712
- University of Texas, Austin
-
接触:
- Eric Crowell, MD MPH
- 电话号码:512-495-5899
- 邮箱:eric.crowell@austin.utexas.edu
-
首席研究员:
- Eric Crowell, MD MPH
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- University of Utah Health
-
接触:
- Marissa Larochelle, MD
- 电话号码:801-581-2352
- 邮箱:marissa.larochelle@hsc.utah.edu
-
首席研究员:
- Marissa Larochelle, MD
-
-
-
-
-
Bristol、英国、BS1 3NU
- University Hospitals Bristol and Weston
-
首席研究员:
- A V Ramanan
-
接触:
- A V Ramanan
- 电话号码:+44 117 3420149
- 邮箱:avramanan@hotmail.com
-
首席研究员:
- Catherine Guly
-
Leicester、英国、LE1 5WW
- University Hospitals of Leicester
-
接触:
- Arani Sridhar
- 邮箱:arani.sridhar@uhl-tr.nhs.uk
-
首席研究员:
- Arani Sridhar
-
首席研究员:
- Bharat Kapoor
-
Liverpool、英国、L14 5AB
- Alder Hey Children's Hospital
-
首席研究员:
- Gavin Cleary
-
首席研究员:
- Jose Gonzalez-Martin
-
接触:
- Jose Gonzalez-Martin
- 电话号码:+44 151 752 5839
- 邮箱:Jose.Gonzalez-Martin@alderhey.nhs.uk
-
London、英国、WC1N 3JH
- Great Ormond Street Hospital
-
首席研究员:
- Elena Moraitis
-
首席研究员:
- Harry Petrushkin
-
接触:
- Elena Moraitis
- 邮箱:elena.moraitis@gosh.nhs.uk
-
副研究员:
- Lola Solebo
-
Manchester、英国、M13 9WL
- Manchester University NHS Foundation Trust
-
接触:
- Jane Ashworth
- 电话号码:+44 794 461 6005
- 邮箱:jane.ashworth@mft.nhs.uk
-
首席研究员:
- Jane Ashworth
-
Newcastle upon Tyne、英国、NE1 4LP
- Great North Children's Hospital
-
首席研究员:
- Sharmila Jandial
-
接触:
- Sharmila Jandial
- 电话号码:+44 191 282 5318
- 邮箱:Sharmila.Jandial@nhs.net
-
Norwich、英国、NR4 6TZ
- Norfolk and Norwich University Hospital
-
首席研究员:
- Kate Armon
-
首席研究员:
- Narman Puvanachandra
-
接触:
- Narman Puvanachandra
- 电话号码:+44 1603288374
- 邮箱:narman.puvanachandra@nnuh.nhs.uk
-
Sheffield、英国、S10 2TQ
- Sheffield Children's Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study period
- History of juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU), diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment)
- ≥2 years of age (per FDA approval for use in children with polyarticular JIA)
- Weight must be ≥15kg
- Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology
- ≥24 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions in either eye)
- ≥24 consecutive months of controlled arthritis verified by a pediatric rheumatologist if defined as JIA-associated uveitis
- ≥24 consecutive months of treatment with adalimumab or biosimilar of adalimumab
- ≥180 days on a stable dose of adalimumab or biosimilar of adalimumab; dose must be no greater than 20mg (if weight <30kg), or 40mg (if weight ≥30kg), injected every two weeks
- If on biosimilar of adalimumab, ≥90 days on the biosimilar
- Ability to continue to obtain commercial supply of adalimumab or biosimilar
- If on a conventional disease-modifying anti-rheumatic drug (cDMARD) (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and route of administration must be stable for ≥90 days
- Willingness to limit consumption of alcohol during the study period
- Agreement to avoid live attenuated vaccinations
- Agreement to use highly effective contraception or abstinence for ≥28 days prior to screening and throughout the study period (for males and females of reproductive age)
- Suitable, in the opinion of the Investigator, to continue treatment with adalimumab/biosimilar per regional labeling
Exclusion Criteria:
- History of acute anterior uveitis characterized by redness and symptoms, including but not limited to floaters, pain, and light sensitivity
- Intraocular surgery in the past 90 days or planned surgery in the next 24 weeks
- Severe cataract or opacity preventing view to the posterior pole in both eyes
- Chronic hypotony (<5mmHg for ≥90 days) in either eye
- Treatment with oral corticosteroids or intraocular corticosteroid injection within the last 24 weeks
- Use of topical corticosteroid eye drops within the last 90 days
- Use of nonsteroidal anti-inflammatory drug (NSAID) eye drops within the last 90 days
- Pregnancy or lactation (a pregnancy test will be conducted at baseline and follow-up visits for females post-menarche)
- Presence of intraretinal or subretinal fluid in either eye
- Prior safety or tolerability issues with adalimumab
- History of cancer, active tuberculosis, or hepatitis B
- Other medical condition expected to dictate treatment course during the study
- Any of the following laboratory test results on their most recent tests within the past 90 days prior to screening/enrollment: leukocyte count <2500, platelet count ≤75000, hemoglobin<9.0, aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 2 times the upper limit of normal range, creatinine ≥1.5
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:2-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 2 weeks for 24 weeks, continuing in accordance with current standard of care practice.
|
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug.
Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection.
All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
|
|
实验性的:4-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 4 weeks for 24 weeks.
|
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug.
Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection.
All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
|
|
实验性的:8-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 8 weeks for 24 weeks.
|
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug.
Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection.
All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
|
|
实验性的:12-Week Dose
Participants receive adalimumab/biosimilar at their current weight-based dose every 12 weeks for 24 weeks.
|
Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody - a biologic, immunomodulatory drug.
Adalimumab (20mg or 40mg) is a clear, colorless solution available as an injectable auto-pen or pre-filled syringe for subcutaneous injection.
All FDA-approved adalimumab biosimilars are allowed for this trial and include: Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cumulative Incidence of Treatment Failure
大体时间:From baseline to 24 weeks post-randomization
|
Proportion of participants in each treatment arm experiencing treatment failure by Week 24. Treatment failure is defined by recurrence of ocular inflammation (at least one of the following in at least one eye):
Treatment failure may also be defined as recurrence of joint disease persistent and severe enough to necessitate unmasking to manage the arthritis recurrence. |
From baseline to 24 weeks post-randomization
|
合作者和调查者
合作者
调查人员
- 首席研究员:Nisha Acharya, MD MS、University of California, San Francisco
出版物和有用的链接
一般刊物
- Quartier P, Baptiste A, Despert V, Allain-Launay E, Kone-Paut I, Belot A, Kodjikian L, Monnet D, Weber M, Elie C, Bodaghi B; ADJUVITE Study Group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018 Jul;77(7):1003-1011. doi: 10.1136/annrheumdis-2017-212089. Epub 2017 Dec 23.
- Pichi F, Smith SD, Goldstein DA, Baddar D, Gerges TKA, Janetos TM, Ruiz-Cruz M, Elena Concha-Del-Rio L, Maruyama K, Carina Ten Berge J, Rombach SM, Cimino L, Bolletta E, Miserocchi E, Scandale P, Serafino M, Camicione P, Androudi S, Gonzalez-Lopez JJ, Lim LL, Singh N, Gupta V, Gupta N, Amer R, Dodds EM, Inchauspe S, Munk MR, Donicova E, Carreno E, Takeuchi M, Chee SP, Chew MC, Agarwal A, Schlaen A, Gomez RA, Couto CA, Khairallah M, Neri P. The Humira in Ocular Inflammations Taper (HOT) Study. Am J Ophthalmol. 2024 Feb;258:87-98. doi: 10.1016/j.ajo.2023.09.012. Epub 2023 Sep 19.
- Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160.
- Acharya NR, Ramanan AV, Coyne AB, Dudum KL, Rubio EM, Woods SM, Guly CM, Moraitis E, Petrushkin HJD, Armon K, Puvanachandra N, Choi JT, Hawley DP, Arnold BF; ADJUST Study Group. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025 Jan 25;405(10475):303-313. doi: 10.1016/S0140-6736(24)02468-1.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 25-45347
- UG1EY038172 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.